Antibiotic Exposure Linked to Shorter Biologic Survival in Psoriasis: A Large French Cohort Suggests a Dose–Response Relationship
Posted inDermatology news

Antibiotic Exposure Linked to Shorter Biologic Survival in Psoriasis: A Large French Cohort Suggests a Dose–Response Relationship

A nationwide retrospective cohort (36,129 patients) found antibiotic use before or during biologic treatment for psoriasis was associated with higher risk of discontinuation or switch; multiple dispensations carried larger risk, suggesting antibiotic-associated dysbiosis may reduce biologic persistence.
Peripheral blood DNA methylation signatures show promise for predicting response to vedolizumab and ustekinumab in Crohn’s disease — EPIC‑CD findings
Posted inGastroenterology news Pathology & Lab Medicine

Peripheral blood DNA methylation signatures show promise for predicting response to vedolizumab and ustekinumab in Crohn’s disease — EPIC‑CD findings

An epigenome-wide study (EPIC‑CD) identified peripheral blood DNA methylation panels that predicted response to vedolizumab and ustekinumab (validated AUC 0.75 each) but failed to predict adalimumab response. Models worked best in biologic‑naïve patients and outperformed available clinical decision support tools.
PANLAR 2025 Recommendations for Polyarticular Juvenile Idiopathic Arthritis in Latin America — Practical, Evidence-Based Guidance for Resource-Variable Settings
Posted inAllergy & Immunology Clinical Updates news Rheumatology Specialties

PANLAR 2025 Recommendations for Polyarticular Juvenile Idiopathic Arthritis in Latin America — Practical, Evidence-Based Guidance for Resource-Variable Settings

PANLAR’s 2025 evidence-based recommendations for non-systemic polyarticular JIA emphasize early treat-to-target care using methotrexate, targeted escalation to biologics when needed, region-sensitive alternatives (leflunomide, triple nbDMARD therapy), and limited steroid bridging to improve outcomes in Latin America.